News & Updates
Filter by Specialty:

Tislelizumab a new Tx alternative for very high-risk bladder cancer?
In the phase II pilot TRUCE-02 trial, tislelizumab plus low-dose nab-paclitaxel shows promising clinical antitumour activity and is well tolerated in patients with extensive very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy (RC).
Tislelizumab a new Tx alternative for very high-risk bladder cancer?
06 Mar 2025
EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer
The updated analysis of the phase III EV-302 trial continues to show the benefit of front-line enfortumab vedotin plus pembrolizumab (EV+P) compared with chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer
05 Mar 2025
Oestradiol patches bump up ADT armamentarium for prostate cancer
Findings from a phase II trial demonstrate the potential of transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT) for men with metastatic (M1) prostate cancer who are on androgen receptor pathway inhibitors (ARPI).